Clinical trials: Lung Fibrosis Interstitial
Idiopathic Pulmonary Fibrosis
Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).
This study is a national, multicenter, interventional, non-randomized, non-controlled, open-label study to assess the effectiveness of pirfenidone in participants with IPF in Russian clinical practice.
- Trial name
- NCT03208933
- Testing
- Pirfenidone
- Where
- 11 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III…
- Trial name
- NCT01619085
- Testing
- Nintedanib
- Where
- 173 sites in United States, Australia and 22 more
- Volunteers
- 752 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT05389215
- Testing
- DWN12088
- Where
- 30 sites in United States, South Korea
- Volunteers
- 102 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Idiopathic Pulmonary Fibrosis
Cough Reduction in IPF With Nalbuphine ER
The main purpose of the study is to evaluate the effect of NAL ER on 24-hour cough frequency using objective digital cough monitoring and to assess safety and tolerability of NAL ER.
- Trial name
- CORAL (NCT05964335)
- Testing
- NAL ER
- Where
- 59 sites in Australia, Canada and 8 more
- Volunteers
- 165 people
- Sponsor
- Trevi Therapeutics
Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01.
- Trial name
- SAIL (NCT06951217)
- Testing
- AP01
- Where
- 92 sites in United States, Argentina and 11 more
- Volunteers
- 340 people
- Sponsor
- Avalyn Pharma Inc.
Idiopathic Pulmonary Fibrosis
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
- Trial name
- NCT05779007
- Testing
- Pirfenidone, Nintedanib
- Where
- United States
- Volunteers
- 2,778 people
- Sponsor
- Boehringer Ingelheim
IPF
A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
AMB-053-01 is a randomized, placebo controlled, multicenter study which will enroll approximately 36 subjects ages 40 and older with IPF for 6 doses over a 24-week dosing period.
- Trial name
- NCT05349760
- Testing
- AMB-05X
- Sponsor
- AmMax Bio, Inc.
Idiopathic Pulmonary Fibrosis
Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging
GSK3008348 is being developed as a treatment for IPF. A first-time-in-human study showed that single nebulized doses of 1-3000 micrograms (mcg) GSK3008348 in healthy volunteers were well tolerated, with pharmacokinetic (PK)…
- Trial name
- NCT03069989
- Testing
- GSK3008348, [18F]-FBA-A20FMDV2
- Where
- 3 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
COVID-19
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19.
- Trial name
- NCT04880109
- Testing
- APX-115
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Aptabio Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease, Asthma
Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects
The first-in-man study are designed as below to assess safety, tolerability, and preliminary pharmacokinetics of ZL-2102. Double-blind randomized, placebo-controlled ascending single oral doses (Part 1, ZL-2102-SAD); Open-label…
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT02397005
- Testing
- ZL-2102
- Where
- Australia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Zai Lab Pty. Ltd.
COPD Asthma, Pulmonary Fibrosis
Accuracy of Spircare Device as Compared to the Conventional Plethysmograph
The purpose of this study is to assess the accuracy of FRC and airway resistance calculate values of Spircare device as compared to the conventional body plethysmograph in healthy adults and patients with obstructive and…
- Trial name
- NCT03056066
- Testing
- Plethysmograph
- Where
- Israel
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Spircare Ltd.
Idiopathic Pulmonary Fibrosis
A Trial of SHR - 1906 in Healthy Subjects
This study is a phase 1 single dose escalation study of SHR-1906 in healthy subjects. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1906 in healthy subjects.
- Trial name
- NCT04986540
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Lung Cancer, Small Cell Lung Cancer
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma
- Trial name
- NCT05337163
- Testing
- Diagnostic Test: Sputum DNA methylation analysis, chest CT or pathological examination
- Where
- China
- Volunteers
- 1,564 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Fibrosis, Lung Disease
Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients
The study is aimed to assess safety of Depelestat treatment, as well as efficacy on prevention and treatment of alveolar inflammation in early pulmonary fibrosis in patients suffering from persistent Acute Respiratory Distress…
- Conditions
- Fibrosis, Lung Disease, Respiratory Disorders, Respiratory Distress Syndrome, Adult
- Trial name
- NCT00455767
- Testing
- EPI-hNE4
- Where
- 14 sites in France, Italy and 2 more
- Volunteers
- 84 people
- Sponsor
- Debiopharm International SA
Fibrosis, Inflammation
A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of RXC007.
- Conditions
- Fibrosis, Inflammation, Idiopathic Pulmonary Fibrosis, Non-alcoholic Steatohepatitis
- Trial name
- NCT04931147
- Testing
- RXC007
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Redx Pharma Ltd
Idiopathic Pulmonary Fibrosis
Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis
To evaluate the efficacy and safety of intravenous SHR-1906 in the treatment of idiopathic pulmonary fibrosis. The study is divided into four stages: screening period, baseline period, treatment period and safe follow-up period.
- Trial name
- NCT05722964
- Testing
- SHR-1906
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis.
- Trial name
- AURORA (NCT06736990)
- Testing
- CAL101
- Where
- 54 sites in United States, Denmark and 9 more
- Volunteers
- 150 people
- Sponsor
- Calluna Pharma AS
IPF, Idiopathic Pulmonary Fibrosis
SB17170 Phase 2 Trial in IPF Patients
This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by…
- Conditions
- IPF, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- NCT06747923
- Testing
- SB17170
- Where
- 5 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- SPARK Biopharma
Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax
Special Drug Use Investigation of Ciproxan Injection in Pediatrics
The objective in this study is collecting post-marketing information on the safety and efficacy of Ciproxan injection under the routine clinical practice.
- Trial name
- NCT02555059
- Testing
- Cipro (Ciprofloxacin, BAYQ3939)
- Where
- Japan
- Volunteers
- 48 people
- Sponsor
- Bayer
Idiopathic Pulmonary Fibrosis
Real-life-persistence to Antifibrotic Treatments
This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence…
- Trial name
- REPEAT (NCT06485635)
- Testing
- Nintedanib, Pirfenidone
- Where
- France
- Volunteers
- 10,646 people
- Sponsor
- Boehringer Ingelheim